CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: A 1H magnetic resonance spectroscopy study

Husarova, Veronika, Bittsansky, Michal, Ondrejka, Igor, Dobrota, Dusan·2014·Psychiatry Research: Neuroimaging
DOI 10.1016/j.pscychresns.2014.03.003
Open this paper in CoChat — free account

Abstract

Attention deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral childhood disorder. Dysfunction of prefrontal neural circuits which are responsible for executive and attentional functions has been previously shown in ADHD. We investigated the neurometablite changes in areas included in dorsolateral prefrontal neural circuits after 2 months of long-acting methylphenidate or atomoxetine medication in children with ADHD who were responders to treatment. Twenty-one ADHD children were examined by single voxel (1)H-magnetic resonance spectroscopy (MRS) before and after 2 months of medication with OROS methylphenidate (n=10) or atomoxetine (n=11). The spectra were taken from the dorsolateral prefrontal cortex (DLPFC, 8ml) and white matter behind the DLPFC (anterior semioval center, 7.5ml), bilaterally. NAA and NAA/Cr (N-acetylaspartate/creatine) decreased in the left DLPFC and Cho/Cr (choline/creatine) increased in the right DLPFC after atomoxetine medication. Glu+Gln and Glu+Gln/Cr (glutamate/glutamine) increased in the left white matter after methylphenidate medication. We hypothesize that atomoxetine could decrease hyperactivation of DLPFC neurons and methylphenidate could lead to increased activation of cortical glutamatergic projections with the consequences of increased tonic dopamine release in the mesocortical system.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pscychresns.2014.03.003

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 10 references

Research works printed but not linked: 43

  1. American Association of Pediatrics, 2000, Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder, Pediatrics, 105, 1158, 10.1542/peds.105.5.1158 · DOI · Paper page
  2. Barton, 2005, Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder, Archives of Disease in Childhood, 90, i26, 10.1136/adc.2004.059386 · DOI
  3. Biederman, 2007, Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder, BMC Psychiatry, 7, 49, 10.1186/1471-244X-7-49 · DOI
  4. Carrey, 2003, Metabolite changes resulting from treatment in children with ADHD: a 1H-MRS study, Clinical Neuropharmacology, 26, 218, 10.1097/00002826-200307000-00013 · DOI
  5. Carrey, 2002, Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series, Journal of Child and Adolescent Psychopharmacology, 12, 331, 10.1089/104454602762599871 · DOI · Paper page
  6. Castellanos, 1994, Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder, Psychiatry Research, 52, 305, 10.1016/0165-1781(94)90076-0 · DOI
  7. Choong, 2004, Methylphenidate restores ventral tegmental area dopamine neuron activity in prenatal ethanol-exposed rats by augmenting dopamine neurotransmission, Journal of Pharmacology and Experimental Therapeutics, 309, 444, 10.1124/jpet.103.060657 · DOI
  8. Courvoisie, 2004, Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings, Journal of Neuropsychiatry and Clinical Neurosciences, 16, 63, 10.1176/jnp.16.1.63 · DOI
  9. Cusack, 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds, Psychopharmacology, 114, 559, 10.1007/BF02244985 · DOI
  10. Dopfner, 2006, Cross-cultural reliability and validity of ADHD assessed by the ADHD rating scale in a pan-European study, European Child and Adolescent Psychiatry, 15, I46, 10.1007/s00787-006-1007-8 · DOI
  11. Faraone, 1998, Neurobiology of attention-deficit hyperactivity disorder, Biological Psychiatry, 44, 951, 10.1016/S0006-3223(98)00240-6 · DOI · Paper page
  12. Fayed, 2007, Evidence of brain dysfunction in attention deficit-hyperactivity disorder: a controlled study with proton magnetic resonance spectroscopy, Academic Radiology, 14, 1029, 10.1016/j.acra.2007.05.017 · DOI
  13. Gainetdinov, 1999, Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity, Science, 283, 397, 10.1126/science.283.5400.397 · DOI · Paper page
  14. Gorelova, 2012, The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral midbrain, Cerebral Cortex, 22, 327, 10.1093/cercor/bhr107 · DOI · Paper page
  15. Husarova, 2010, Potential pathomechanisms of ADHD based on neurometabolite changes, Neuro-endocrinology Letters, 31, 438
  16. Jin, 2001, Striatal neuronal loss or dysfunction and choline rise in children with attention-deficit hyperactivity disorder: a 1H-magnetic resonance spectroscopy study, Neuroscience Letters, 315, 45, 10.1016/S0304-3940(01)02315-1 · DOI
  17. Kobayashi, 2010, Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine, Neuropsychopharmacology, 35, 1560, 10.1038/npp.2010.27 · DOI
  18. Kronenberg, 2008, Increased NAA and reduced choline levels in the anterior cingulum following chronic methylphenidate. A spectroscopic test-retest study in adult ADHD, European Archives of Psychiatry and Clinical Neuroscience, 258, 446, 10.1007/s00406-008-0810-2 · DOI
  19. Kukley, 2007, Vesicular glutamate release from axons in white matter, Nature Neuroscience, 10, 311, 10.1038/nn1850 · DOI
  20. Ledbetter, 2006, Atomoxetine: a novel treatment for child and adult ADHD, Neuropsychiatric Disease and Treatment, 2, 455, 10.2147/nedt.2006.2.4.455 · DOI
  21. Levy, 2004, Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety, Neuropsychopharmacology, 29, 1589, 10.1038/sj.npp.1300469 · DOI
  22. Ludolph, 2010, Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations, British Journal of Pharmacology, 160, 283, 10.1111/j.1476-5381.2010.00707.x · DOI
  23. MacMaster, 2003, Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder, Biological Psychiatry, 53, 184, 10.1016/S0006-3223(02)01401-4 · DOI
  24. Mason, 2006, MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases, NMR Biomedicine, 19, 690, 10.1002/nbm.1080 · DOI
  25. Mattingly, 2013, Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder, BMC Psychiatry, 13, 39, 10.1186/1471-244X-13-39 · DOI
  26. Max, 2005, Prefrontal and executive attention network lesions and the development of attention-deficit/hyperactivity symptomatology, American Academy of Child and Adolescent Psychiatry, 44, 443, 10.1097/01.chi.0000156661.38576.0f · DOI
  27. Oades, 2005, The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles, Developmental Science, 8, 122, 10.1111/j.1467-7687.2005.00399.x · DOI
  28. Podet, 2010, Nucleus accumbens lesions modulate the effects of methylphenidate, Brain Research Bulletin, 82, 293, 10.1016/j.brainresbull.2010.05.006 · DOI
  29. Prieto-Gomez, 2005, Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area, Life Sciences, 77, 635, 10.1016/j.lfs.2004.10.076 · DOI
  30. Rakic, 2002, Neurogenesis in adult primate neocortex: an evaluation of the evidence. Nature Reviews, Neuroscience, 3, 65
  31. Rigotti, 2007, Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders, AJNR American Journal of Neuroradiology, 28, 1843, 10.3174/ajnr.A0774 · DOI
  32. Rubia, 2001, Neuropsychological analyses of impulsiveness in childhood hyperactivity, British Journal of Psychiatry, 179, 138, 10.1192/bjp.179.2.138 · DOI
  33. Sagvolden, 1998, Attention deficit/hyperactivity disorder – from brain dysfunctions to behaviour, Behavioural Brain Research, 94, 1
  34. Soutullo, 2013, A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents, CNS Drugs, 27, 743, 10.1007/s40263-013-0086-6 · DOI
  35. Szabo, 2001, Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus, Neuropsychopharmacology, 25, 845, 10.1016/S0893-133X(01)00284-6 · DOI
  36. Tafazoli, 2013, 1H MRSI of middle frontal gyrus in pediatric ADHD, Journal of Psychiatric Research, 47, 505, 10.1016/j.jpsychires.2012.11.011 · DOI
  37. Tehrani-Doost, 2008, An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder, Journal of Child and Adolescent Psychopharmacology, 18, 179, 10.1089/cap.2006.0034 · DOI
  38. Volkow, 1999, Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain, Life Sciences, 65, PL7, 10.1016/S0024-3205(99)00225-8 · DOI
  39. Wanchoo, 2009, Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate, Brain Research, 1301, 68, 10.1016/j.brainres.2009.08.095 · DOI
  40. Wiguna, 2012, Effect of 12-week administration of 20-mg long-acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school-age children in Indonesia: a study using 1H magnetic resonance spectroscopy (MRS), Clinical Neuropharmacology, 35, 81, 10.1097/WNF.0b013e3182452572 · DOI · Paper page
  41. Yang, 2010, Short-TE proton magnetic resonance spectroscopy investigation in adolescents with attention-deficit hyperactivity disorder, Psychiatry Research: Neuroimaging, 181, 199, 10.1016/j.pscychresns.2009.10.001 · DOI
  42. Yeo, 2003, Proton magnetic resonance spectroscopy investigation of the right frontal lobe in children with attention-deficit/hyperactivity disorder, Journal of the American Academy of Child and Adolescent Psychiatry, 42, 303
  43. Ziskin, 2007, Vesicular release of glutamate from unmyelinated axons in white matter, Nature Neuroscience, 10, 321, 10.1038/nn1854 · DOI

Cited by

Sorted by citations

See all 19

Metadata

Authors
Husarova, V., Bittsansky, M., Ondrejka, I., & Dobrota, D.
Venue
Psychiatry Research: Neuroimaging
Publisher
Elsevier BV
Published
2014-04
Volume
222
Issue
1-2
Pages
75-83
ISSN
0925-4927
DOI
10.1016/j.pscychresns.2014.03.003
Cited by
19
References
10
Language
en
Licence
Funders
  • Ministry of Education (2007/57-UK-17, 26220120053)
  • Univerzita Komenského v Bratislave (APVV-0254-11, UK/251/2012)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review